CD30 is required for activation of a unique subset of interleukin-17A-producing ?? T cells in innate immunity against Mycobacterium bovis Bacillus Calmette-Guerin infection.
Ontology highlight
ABSTRACT: Interleukin-17A (IL-17A)-producing ?? T cells are known to be activated following Mycobacterium bovis bacillus Calmette-Guérin (BCG) infection. Here, we show that CD30, a member of the tumor necrosis factor (TNF) receptor superfamily, is important for activation of IL-17A-producing ?? T cells after BCG infection. V?1(-) V?4(-) ?? T cells preferentially expressing V?6/V?1 genes were identified as the major source of IL-17A in the peritoneal cavity during the early stage of BCG infection. The number of IL-17A-producing V?1(-) V?4(-) ?? T cells bearing V?6 increased in peritoneal exudate cells (PEC) of wild-type (WT) mice but not in those of CD30 knockout (KO) mice in response to BCG infection. Consistently, CD30 ligand (CD30L) or CD30 expression, predominantly by V?1(-) V?4(-) ?? T cells, was rapidly upregulated after BCG infection. Inhibition of CD30L/CD30 signaling by in vivo administration of a soluble CD30 and immunoglobulin fusion protein (CD30-Ig) severely impaired activation of IL-17A-producing V?1(-) V?4(-) ?? T cells in WT mice, while stimulating CD30L/CD30 signaling by in vivo administration of agonistic anti-CD30 monoclonal antibody (MAb) restored IL-17A production by V?1(-) V?4(-) ?? T cells in CD30L KO mice after BCG infection. These results suggest that CD30 signaling plays an important role in the activation of IL-17A-producing V?1(-) V?4(-) ?? T cells bearing V?6 at an early stage of BCG infection.
SUBMITTER: Guo Y
PROVIDER: S-EPMC3811784 | biostudies-other | 2013 Oct
REPOSITORIES: biostudies-other
ACCESS DATA